Targets › SLC18A2
5 programs from 5 companies in 7 trials: 5 Phase 2, 2 Phase 4; Neurology, Psychiatry, Metabolic and endocrine; next expected readout Jun 2027.
Electrogenic antiporter that exchanges one cationic monoamine with two intravesicular protons across the membrane of secretory and synaptic vesicles. Uses the electrochemical proton gradient established by the V-type proton-pump ATPase to accumulate high concentrations of monoamines inside the vesicles prior to their release via exocytosis. (UniProt, Q05940)
Open in Phaseline: the race on SLC18A2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University Hospitals Cleveland Medical Center | Deutetrabenazine Synaptic vesicular amine transporter inhibitor | SLC18A2 | Phase 4 | Tardive Dyskinesia | Oct 2027 |
| Neurocrine Biosciences | Valbenazine Synaptic vesicular amine transporter inhibitor | SLC18A2 | Phase 4 | Schizophrenia; Trichotillomania (Hair-Pulling Disorder); Cervical Dystonia | Jun 2028 |
| Vanderbilt University Medical Center | Deutetrabenazine Synaptic vesicular amine transporter inhibitor | SLC18A2 | Phase 2 | Huntington Disease | Jun 2027 |
| Medical University of Lodz | Lisdexamfetamine Dopamine transporter releasing agent; Norepinephrine transporter releasing agent; Synaptic vesicular amine transporter inhibitor | SLC6A3, SLC6A2, SLC18A2 | Phase 2 | Attention Deficit Disorder with Hyperactivity | Dec 2027 |
| Centre hospitalier de l'Université de Montréal (CHUM) | Lisdexamfetamine Dopamine transporter releasing agent; Norepinephrine transporter releasing agent; Synaptic vesicular amine transporter inhibitor | SLC6A3, SLC6A2, SLC18A2 | Phase 2 | Methamphetamine Abuse | Dec 2027 |
Schizophrenia (1) Trichotillomania (Hair-Pulling Disorder) (1) Cervical Dystonia (1) Huntington Disease (1) Attention Deficit Disorder with Hyperactivity (1) Tardive Dyskinesia (1) Methamphetamine Abuse (1)
small molecule (5)
Neurocrine Biosciences (1) Vanderbilt University Medical Center (1) Medical University of Lodz (1) University Hospitals Cleveland Medical Center (1) Centre hospitalier de l'Université de Montréal (CHUM) (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.